The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
BioMarin Pharmaceutical Inc
XMUN:BM8
|
US |
|
Sprout Social Inc
NASDAQ:SPT
|
US |
|
E
|
Eli Lilly and Co
F:LLY
|
US |
|
P
|
PICC Property and Casualty Co Ltd
OTC:PPCCF
|
CN |
|
Norsk Titanium AS
F:84F
|
NO |
|
P
|
Prymus SA
WSE:PRS
|
PL |
|
Microstrategy Inc
NASDAQ:MSTR
|
US |
|
M
|
Mitra Adiperkasa Tbk PT
F:QGI
|
ID |
|
Societatea de Producere a Energiei Electrice in Hidrocentrale Hidroelectrica SA
F:E28
|
RO |
|
SiTime Corp
NASDAQ:SITM
|
US |
|
Nanoveu Ltd
ASX:NVU
|
AU |
|
M
|
Maple Leaf Foods Inc
F:M1L
|
CA |
|
H
|
Hong Kong Exchanges and Clearing Ltd
F:HK2C
|
HK |
|
A
|
Adler Group SA
DUS:ADJ
|
LU |
|
E
|
Eurosnack SA
WSE:ECK
|
PL |
|
Orange SA
PAR:ORA
|
FR |
|
Insulet Corp
NASDAQ:PODD
|
US |
|
T
|
Thachang Green Energy PCL
SET:TGE
|
TH |
|
M
|
Meiko Electronics Co Ltd
F:MEC
|
JP |
|
Farmhouse Inc
OTC:FMHS
|
US |
|
Sin Heng Heavy Machinery Ltd
SGX:BKA
|
SG |
|
A
|
AirBoss of America Corp
OTC:ABSSF
|
CA |
|
Millennium Bankshares Corp
OTC:MBVA
|
US |
|
P
|
Puma SE
DUS:PUM
|
DE |
BioMarin Pharmaceutical Inc (BM8)’s 12-month stock price forecast through November 2027 has a consensus target of €87.56, implying 67% upside. The forecast is based on price targets from 30 Wall Street analysts.
Past growth per year Not enough data
Average annual growth cannot be calculated for these periods.
Explore analyst estimates, growth and forecast ranges.
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
According to Wall Street analysts, the average 1-year price target for
BM8 is 87.56 EUR with a low forecast of 58.02 EUR and a high forecast of 122.64 EUR.
Over the last 13 years, the compound annual growth rate for Revenue has been 15%. The projected CAGR for the next 8 years is 9%.
Over the last 13 years, the compound annual growth rate for Gross Profit has been 15%. The projected CAGR for the next 8 years is 9%.
The compound annual growth rate for Operating Income over the next 8 years is 15%.
The compound annual growth rate for Pre-Tax Income over the next 3 years is 47%.
The compound annual growth rate for Net Income over the next 8 years is 25%.
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.
Read more